GLOW (70 mg Blend)

The GLOW peptide blend (GHK-Cu, BPC-157, TB-500) is dosed at approximately 2.33 mg daily via subcutaneous administration in educational protocols. A 70 mg blend reconstituted with bacteriostatic water yields roughly 23.3 mg/mL. Cycles typically run 4–8 weeks. This information is for research and educational use only.

Educational guide for Research Preparation Information and daily dosing.

Standard Approach (3 mL = 23.3 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–4	2,330 mcg	10 units (0.10 mL)

Frequency: Inject once daily subcutaneously. This schedule maintains a consistent dose throughout the 4-week cycle. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1 . Draw 3.0 mL bacteriostatic water with a sterile syringe.
2 . Inject slowly down the vial wall to minimize foaming.
3 . Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
4 . Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F).
5 . Use within 4 weeks for optimal potency and safety.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on a 4-week daily protocol at standard dosing.

Concise summary of the once-daily regimen.

Goal: Support comprehensive tissue healing through synergistic peptide mechanisms—collagen synthesis (GHK-Cu), cell migration and angiogenesis (TB-500), and localized repair with anti-inflammatory effects (BPC-157).
Schedule: Daily subcutaneous injections for 4 weeks at a consistent dose, followed by a 2–4 week rest period to assess progress before considering another cycle.
Dose Range: 2,330 mcg (2.33 mg) total blend daily, providing approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection.
Research Preparation Information: 3.0 mL per 70 mg vial (23.3 mg/mL) for precise unit measurements.
Storage: Lyophilized vials frozen; reconstituted solutions refrigerated; use within 4 weeks.

Straightforward daily dosing approach for balanced peptide delivery.

Daily Dose: 2,330 mcg (10 units / 0.10 mL) maintained throughout the 4-week cycle.
Frequency: Once per day (subcutaneous), at a consistent time preferred.
Cycle Length: 4 weeks of daily dosing, followed by 2–4 weeks off to evaluate progress and allow receptor resetting.
Volume: Per Research Procedure, volume (~0.1 mL) is well below the 1.0–1.5 mL comfort threshold for subcutaneous administration.
Syringe Recommendation: Use 0.3 mL (30-unit) insulin syringes for greater measurement precision at low volumes.

Proper storage preserves peptide stability and potency.

Lyophilized: Store at −20 °C (−4 °F) or below for long-term stability (months to over a year). If a freezer is unavailable, refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for shorter durations (weeks). Store in a sealed container with desiccant if possible to prevent moisture absorption.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) at all times when not in use. Do not freeze reconstituted solution. Use within 4 weeks (28 days) for optimal potency and safety. Discard any unused solution after this period.
Allow frozen vials to reach room temperature before opening to prevent condensation.
Protect reconstituted solution from light (store in amber vial or wrap in foil).
Inspect solution before each use; discard if discolored, cloudy, or contains precipitate.

Practical considerations for safe and effective administration.

Use new sterile insulin syringes for each Research Procedure; dispose in a sharps container immediately after use.
Rotate Research Procedure sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipo-hypertrophy.
Inject slowly over 2–3 seconds and wait a few seconds before withdrawing the needle to ensure complete delivery.
Document daily dose, Research Procedure site, and any observations to maintain consistency and track progress.
Practice aseptic technique at every Research Procedure: clean vial stopper and skin with separate alcohol swabs, allow to air-dry completely.

The three peptides in GLOW operate via distinct but complementary biological pathways to enhance healing and repair. GHK-Cu acts as a genomic modulator—it can upregulate a broad array of genes related to tissue growth and downregulate those linked to inflammation and tissue breakdown. Notably, GHK-Cu stimulates collagen and glycosaminoglycan synthesis in fibroblasts, promotes angiogenesis (formation of new blood vessels), and exhibits antioxidant and anti-inflammatory properties (for example, it suppresses NF-κB activity). These actions translate to improved wound contraction, tissue remodeling, and even anti-aging effects in skin.

TB-500 (Thymosin β4) primarily facilitates cell migration and cytoskeletal remodeling. After an injury, endogenous thymosin β4 is released by platelets and immune cells to protect tissues from further damage. TB-500 mimics this by binding to actin, a key cell structural protein, and promoting the mobilization of cells to the injury site. It thereby accelerates angiogenesis (new capillary growth) and recruits stem and progenitor cells, which aid in regenerating damaged tissues. TB-500 also has anti-apoptotic effects (reducing cell death) and modulates immune cells to limit excessive inflammation and fibrosis. One outcome of this mechanism is reduced scar tissue formation and more organized healing in wounds.

BPC-157 triggers a multi-factorial healing response. It is known to enhance growth factor signaling (e.g., increasing receptors for VEGF and PDGF) and upregulate nitric oxide pathways, leading to improved microcirculation in injured tissue. BPC-157 also directly counteracts inflammatory mediators—it lowers pro-inflammatory cytokines and increases anti-inflammatory factors at injury sites. On a cellular level, BPC-157 promotes the migration and survival of repair cells (fibroblasts, endothelial cells, etc.). For instance, in tendon cells it activates the FAK-paxillin pathway to increase cell movement and adhesion for repair. Additionally, BPC-157 supports the formation of new blood vessels (angiogenesis) similar to growth factors, helping deliver nutrients for regeneration. Through these mechanisms, BPC-157 has demonstrated accelerated healing in diverse tissues (muscle, tendon, bone, gut) in preclinical models.

By combining GHK-Cu, TB-500, and BPC-157, GLOW leverages these synergistic pathways—collagen synthesis, cell migration, angiogenesis, and inflammation control—to create an optimal environment for tissue repair. The net result observed in research is faster wound closure, stronger tissue regeneration, and reduced fibrosis compared to normal healing processes.

Observations from preclinical and clinical literature on the component peptides.

Accelerated Wound Healing: All three components have shown the ability to speed up the repair of injuries. Thymosin β4 significantly improved the closure rate of chronic skin wounds in clinical trials and animal models, while also reducing excessive scar formation. BPC-157 has demonstrated enhanced healing in tendon ruptures, muscle tears, bone fractures, and even stomach ulcers in preclinical studies. GHK-Cu likewise aids wound contraction and epithelialization in skin, promoting faster regeneration of damaged tissue.
Anti-Inflammatory & Pain Reduction: Each peptide has inherent anti-inflammatory effects that can mitigate pain and swelling at injury sites. GHK-Cu downregulates inflammation-related genes (like NF-κB) and has been noted to reduce oxidative damage and even pain behaviors in studies. TB-500 suppresses key inflammatory cytokines (such as IL-6, TNF-α) and was shown to create a more anti-inflammatory healing environment. BPC-157 markedly dampens tissue inflammation in injury models, which contributes to less edema and discomfort during recovery.
Improved Tissue Quality & Reduced Fibrosis: TB-500 helps minimize fibrous scar tissue in healing wounds—it was observed to decrease myofibroblast accumulation, leading to more orderly tissue architecture and less scarring. BPC-157 has similarly been associated with organized collagen deposition in injured muscle and tendon, resulting in stronger, more functional repair tissue. GHK-Cu contributes by boosting proper collagen and extracellular matrix production. Collectively, the blend supports higher quality healing—meaning repaired tissues more closely resemble the original, with better tensile strength and flexibility.
Multi-Tissue Regeneration: A unique advantage of the GLOW blend is its applicability to various tissues and systems, from orthopedic injuries (tendon, ligament tears, muscle strains, fractures) to dermatologic uses (skin rejuvenation, wound care) and potentially gastrointestinal repair (ulcers, gut lining integrity).
Tolerability: Generally well tolerated based on existing research. Occasional mild Research Procedure -site reactions (redness, itching) may occur with subcutaneous administration. The component peptides have demonstrated wide safety margins in preclinical and early clinical studies

Note: These benefits are based on emerging research. Large-scale human clinical trials are still needed to confirm efficacy and safety for specific indications.

Complementary strategies to optimize tissue healing outcomes.

Maintain adequate protein intake (1.6–2.2 g/kg body weight daily) to support collagen synthesis and tissue repair.
Implement progressive resistance training and appropriate activity modification based on healing goals.
Prioritize sleep quality (7–9 hours nightly) as the primary recovery window for tissue regeneration.
Manage stress through evidence-based techniques to support optimal healing hormonal environment.
Stay well-hydrated and ensure adequate micronutrient intake, particularly vitamin C, zinc, and copper for collagen formation.

Subcutaneous Research Procedure guidance based on clinical best practices

Clean the vial stopper and Research Procedure site with separate alcohol swabs; allow both to air-dry completely.
Using an insulin syringe (typically 29–31 gauge, 5/16 to 1/2 inch needle), draw up the calculated dose (10 units = 0.1 mL).
Select a site with adequate subcutaneous tissue (common sites include lower abdomen, thigh, or upper arm).
Pinch a fold of skin; insert the needle at approximately a 45° angle into the fatty subcutaneous tissue. With short insulin needles, a 90° angle can also be used if injecting into a pinched skin fold.
Inject slowly over 2–3 seconds; do not aspirate for subcutaneous Research Procedure.
Withdraw needle and apply gentle pressure with a clean cotton swab; do not rub the Research Procedure site.
Rotate sites systematically with each Research Procedure, maintaining at least 1–2 inches spacing between sites to prevent tissue irritation.
Dispose of used syringes and needles immediately in a proper sharps container; never reuse needles.

For product-specific information, availability, or additional support, please contact us on Telegram.

Why Vitality Labs?

This content is provided for general educational and research reference only. It does not constitute medical advice, diagnosis, treatment guidance, dosage guidance, or usage instruction.

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

International Journal of Molecular Sciences

— Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (2018)

International Journal of Medical Sciences

— Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review (2025)

Vitamins & Hormones (PubMed)

— Thymosin β4 Promotes Dermal Healing (2016)

Expert Opinion on Biological Therapy (PubMed)

— Thymosin β4: A Multi-Functional Regenerative Peptide. Basic Properties and Clinical Applications (2012)

HSS Journal (PMC)

— Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025)

Journal of Applied Physiology (PubMed)

— The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival, and Cell Migration (2011)

Immunize.org (IAC)

— Ask the Experts: Administering Vaccines – Subcutaneous Route Q&A (2025)

Bachem Peptide Technical Guide

— Handling and Storage Guidelines for Peptides (2023)

CDC Pink Book (14th Edition)

— General Best Practice Guidelines for Immunization – Vaccine Administration (Subcutaneous Research Procedure (2022)

GLOW (70 mg Blend)

GLOW (70 mg Blend)​

Standard Approach (3 mL = 23.3 mg/mL)

Why Vitality Labs?

International Journal of Molecular Sciences

International Journal of Medical Sciences

Vitamins & Hormones (PubMed)

Expert Opinion on Biological Therapy (PubMed)

HSS Journal (PMC)

Journal of Applied Physiology (PubMed)

Immunize.org (IAC)

Bachem Peptide Technical Guide

CDC Pink Book (14th Edition)

BPC-157 + TB-500 (20 mg Blend) Product Information Guide

BPC-157 (5 mg Vial) Product Information Guide

BPC-157 (10 mg Vial) Product Information Guide

TB-500 (10 mg Vial) Product Information Guide

TB-500 (5 mg Vial) Product Information Guide

GLOW (70 mg Blend)